Turning Point Therapeutics (Turning Point Therapeutics) Total Assets : $843.34 Mil (As of Jun. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Turning Point Therapeutics Total Assets?

Turning Point Therapeutics's Total Assets for the quarter that ended in Jun. 2022 was $843.34 Mil.

During the past 12 months, Turning Point Therapeutics's average Total Assets Growth Rate was -0.30% per year. During the past 3 years, the average Total Assets Growth Rate was 113.40% per year.

During the past 5 years, Turning Point Therapeutics's highest 3-Year average Total Assets Growth Rate was 153.20%. The lowest was 113.40%. And the median was 133.30%.

Total Assets is connected with ROA %. Turning Point Therapeutics's annualized ROA % for the quarter that ended in Jun. 2022 was -55.25%. Total Assets is also linked to Revenue through Asset Turnover. Turning Point Therapeutics's Asset Turnover for the quarter that ended in Jun. 2022 was 0.00.

Turning Point Therapeutics Total Assets Historical Data

The historical data trend for Turning Point Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics Total Assets Chart

Turning Point Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Total Assets

45.91

103.28

422.20

1,136.71

1,003.46

Turning Point Therapeutics Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Total Assets	Get a 7-Day Free Trial														1,102.92	1,058.99	1,003.46	938.79	843.34

Turning Point Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Turning Point Therapeutics's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as

Total Assets	=	Total Equity (A: Dec. 2021 )	+	Total Liabilities (A: Dec. 2021 )
	=	954.425	+	49.038
	=	1,003.46

Turning Point Therapeutics's Total Assets for the quarter that ended in Jun. 2022 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2022 )	+	Total Liabilities (Q: Jun. 2022 )
	=	793.022	+	50.313
	=	843.34

Turning Point Therapeutics (NAS:TPTX) Total Assets Explanation

Total Assets is connected with ROA %.

Turning Point Therapeutics's annualized ROA % for the quarter that ended in Jun. 2022 is

ROA %	=	Net Income (Q: Jun. 2022 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Jun. 2022 ))	/ count )
	=	-492.352	/	( (938.786	+	843.335)	/ 2 )
	=	-492.352	/	891.0605
	=	-55.25 %

Note: The Net Income data used here is four times the quarterly (Jun. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Turning Point Therapeutics's Asset Turnover for the quarter that ended in Jun. 2022 is

	Asset Turnover
=	Revenue (Q: Jun. 2022 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Jun. 2022 ))	/ count )
=	0.119	/	( (938.786	+	843.335)	/ 2 )
=	0.119	/	891.0605
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Turning Point Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Turning Point Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Turning Point Therapeutics (Turning Point Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turning Point Therapeutics Inc (NAS:TPTX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.tptherapeutics.com

Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.

Executives

Paolo Tombesi	officer: EVP & Chief Financial Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Steve M Sabus	officer: SVP & Chief Commercial Officer	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Brian Sun	officer: SVP & General Counsel	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Mohammad Hirmand	officer: EVP and Chief Medical Officer	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Athena Countouriotis	director, officer: President & CEO	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Siegfried Reich	officer: EVP & Chief Scientific Officer	10505 ROSELLE STREET SAN DIEGO CA 92121
Andrew John Partridge	officer: EVP & Chief Commercial Officer	C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109
Annette North	officer: EVP, General Counsel & Secty.	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Van Hoose Kyri K.	officer: Principal Accounting Officer	C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Brian Lee Baker	officer: VP of Finance and Admin.	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Yi Larson	officer: EVP & Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Jingrong Jean Cui	director, 10 percent owner, officer: Chief Scientific Officer	C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428